[ad_1]
One of Cork’s oldest pharmaceutical companies and the largest employers in the industry will create 300 new jobs in Ireland, with a significant number coming to Leeside.
Taoiseach Micheál Martin announced the huge expansion plan this morning with especially good news for Cork along with Pfizer’s operations in Kildare and Dublin.
Work will begin shortly on a major new facility at Ringaskiddy, which will manufacture pharmaceutical compounds for Pfizer clinical trials globally, expanding the company’s role in Ireland to support earlier phases of new drug development.
It’s a huge investment for the future of the global giant’s Cork operations, and comes as major manufacturing of covid-19 vaccines is expected to begin.
Pfizer announced this morning the investment of approximately 300 million euros in its Irish operations, creating 300 new positions in Dublin, Kildare and Cork.
The investment will support the expansion of the company’s existing manufacturing sites at Grange Castle in Dublin, Newbridge and Ringaskiddy, and will also include the initial construction phase of an additional development facility at the Ringaskiddy site.
Pfizer’s Irish sites manufacture vaccines and drugs in the areas of arthritis, inflammation, cancer, anti-infectives, hemophilia, pain, and stroke.
The 300 new positions will be filled over the next two to three years and will bring the total number of companies in Ireland to 4,000.
The new hires will include highly skilled roles such as analysts, technicians, engineers, scientists, technologists, quality control, data analysts and chemists.
Speaking at the announcement at government buildings in Dublin, Taoiseach Micheál Martin, TD, said the plan was a vote of confidence in the skills and talents of the Irish.
“Over the past five decades, there has been a huge expansion of the industry in this country, creating thousands of jobs and solidifying Ireland’s reputation as a world leader in pharmaceutical manufacturing and innovation.”
“Pfizer has made a significant contribution to the Irish economy and this latest investment is a testament to the quality and expertise of the workforce here.”
IDA Ireland CEO Martin Shanahan said the investment “underscores Ireland’s reputation as a global place of excellence for biopharmaceuticals.”
Dr. Paul Duffy, vice president of Pfizer Global Supply, said it was “particularly exciting” that the company’s Ringaskiddy site has been chosen to manufacture investigational compounds for its clinical trials worldwide.
The IDA chief added: “We look forward to seeing the new facility come online.”
[ad_2]